Patents by Inventor Joseph A. Rininger

Joseph A. Rininger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6140063
    Abstract: The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur.
    Type: Grant
    Filed: August 13, 1998
    Date of Patent: October 31, 2000
    Assignee: Paracelsian, Inc.
    Inventors: Geoffrey D. Wheelock, Joseph Rininger, John G. Babish, Padmasree Chigurupati
  • Patent number: 5955289
    Abstract: In vivo and in vitro assays for the detection and quantification of substances, which are carcinogenic, but not genotoxic or mutagenic, by measuring a correlative change in cyclin dependent kinases (CDK).
    Type: Grant
    Filed: March 7, 1995
    Date of Patent: September 21, 1999
    Assignee: Brown, Pinnisi & Michaels, PC
    Inventors: Xinfang Ma, Joseph A. Rininger, Brian E. Johnson, Debra S. Whiting
  • Patent number: 5833994
    Abstract: The present invention includes the method of treating a viral infection, specifically one occurring as a result of infection by a human immunodeficiency virus (HIV-1). The method of treatment depends upon the ligand binding of the Ah receptor. Transformation and translocation of the receptor and DNA binding are not required. The study of compounds that interact with the Ah receptor, either as agonists, or antagonists, has resulted in the identification of compounds with useful therapeutic properties through perturbation of viral pathogenic signal transduction pathways. Antagonists of the Ah receptor are more likely candidates for treatment because the toxicity of such compounds is low. Identification of molecules affecting cellular targets, such as the Ah receptor, that inhibit viral pathologic signaling would be of great therapeutic potential as the activity of these molecules is not directed against the virus itself, therefore genetic viral mutation to escape such therapy would be far less likely to occur.
    Type: Grant
    Filed: January 8, 1997
    Date of Patent: November 10, 1998
    Assignee: Paracelsian, Inc.
    Inventors: Geoffrey D. Wheelock, Joseph Rininger, John G. Babish, Padmasree Chigurupati